Financials data is unavailable for this security.
View more
Year on year ImmuCell Corp 's revenues fell -5.90% from 18.57m to 17.47m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 2.49m to a larger loss of 5.77m.
Gross margin | 26.05% |
---|---|
Net profit margin | -17.44% |
Operating margin | -15.11% |
Return on assets | -9.43% |
---|---|
Return on equity | -16.10% |
Return on investment | -10.50% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at ImmuCell Corp fell by 4.81m. Cash Flow from Financing totalled 1.75m or 10.02% of revenues. In addition the company used 4.67m for operations while cash used for investing totalled 1.89m.
Cash flow per share | -0.172 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.99 |
---|---|
Tangible book value per share | 2.98 |
More ▼
Balance sheet in USDView more
Current ratio | 2.37 |
---|---|
Quick ratio | 0.7668 |
Total debt/total equity | 0.48 |
---|---|
Total debt/total capital | 0.3243 |
More ▼